Biotech venture funding – Is all venture money created equal?

11.00 - 11.45 Friday 7 December

 

Is all Venture money created equal? Find out why certain investors won't be interested in certain investment opportunities, why different sorts of investors have to focus their funds in different ways, hear how these investors would recommend CEOs should approach them for funding, and what to expect once you speak to venture investors. 

 

Ashish Patel, Investment manager, Mercia Technologies

 

 

Clare Terlouw

Head of Corporate Development

Syncona Partners

Clare is Head of Corporate Development at Syncona, a FTSE 250 company that founds, builds and funds businesses in innovative areas of healthcare, taking a long-term view to build global leaders in life science. With over 20 years’ experience in the healthcare industry, including 15 years as a specialist healthcare and life sciences corporate financier in London, she was previously a Managing Director in Healthcare & Life Sciences Corporate Advisory and Broking at Numis Securities. She focused on advising London Stock Exchange Main Market and AIM-listed healthcare and life sciences companies, specialising in ECM corporate advisory and broking, M&A, and private placements. Clare also previously worked at Nomura Code and Peel Hunt. Prior to investment banking she was an orthopaedic physiotherapist treating patients for acute sport and trauma injuries.

Jeremy Curnock Cook

Managing Director

BioScience Managers

Jeremy is passionate about investing today for a healthier tomorrow and bringing tangible benefits to people across the world.
As a veteran in the life sciences/healthcare industry he has been actively supporting the commercialisation of healthcare innovations and helping entrepreneurs build their international businesses over the past 35 years.

Founder and Managing Director of BioScience Managers, Jeremy brings his decades of international experience to our investment team, to support the identification of investment opportunities and in the strategic assessment of value creation options, in particular through M&A and expansion into new geographies. He actively supports portfolio companies through his executive and non-executive roles.

Over his career, Jeremy has successfully managed in excess of US$1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan and Australia.

Genghis Lloyd-Harris

Partner

Abingworth

Genghis identifies and invests in new businesses and supports portfolio companies. He focuses on exits of venture investments via mergers and acquisitions and IPOs. Genghis’ current and past board positions include Avillion, GenSight Biologics, Healthcare Brands International, Nouscom, Novexel, Solexa, Synosia, Syntaxin and Wilson Therapeutics.
Genghis joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) where he was a Managing Director in the European Equity Research Group based in London. Genghis was responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to 2003. Before joining Equity Research at CSFB, he worked for CSFB’s Health Care Group in the Investment Banking Division in New York. Genghis was previously a paediatrician in Melbourne, Australia. Genghis holds a Medical Degree from the University of Liverpool in the UK, a PhD in Clinical Pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School.

 

Register